eRF1 Activators
eRF1 activators are a category of chemical compounds that interact with the eukaryotic release factor 1 (eRF1), which is a pivotal component in the process of biological translation termination. The biological translation is the process by which ribosomes synthesize proteins by decoding the messenger RNA (mRNA). During this process, eRF1 plays a crucial role in recognizing stop codons-specific sequences of three nucleotides in the mRNA that signal the end of the protein-coding sequence. When a stop codon is reached, eRF1 binds to the A site of the ribosome, inducing a cascade of molecular interactions that lead to the release of the newly synthesized polypeptide chain. eRF1 activators, therefore, are molecules that enhance the activity of eRF1, increasing its ability to recognize stop codons and promoting the termination of protein synthesis. By altering the efficiency of eRF1, these activators can influence the fidelity and regulation of protein synthesis at a fundamental level.
The mechanistic action of eRF1 activators involves binding to the eRF1 or modulating its interaction with other components of the translation termination complex, such as eRF3 and GTP, which together form a termination complex. These activators might affect the conformational dynamics of eRF1, which is essential for its stop codon recognition capability and the peptidyl transferase activity of the ribosome. By stabilizing the correct conformation or by enhancing the binding affinity of eRF1 to the stop codon, the activators play a significant role in ensuring that the translation process is concluded accurately and efficiently. It is important to note that this interaction is highly specific and must be finely regulated, as eRF1's activity is critical to maintaining the integrity of the genetic code and ensuring that protein synthesis is meticulously controlled. Hence, eRF1 activators, by modulating the termination phase of protein synthesis, are central to the maintenance of cellular homeostasis and the precise expression of genetic information.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide is a known inhibitor of the eukaryotic protein biosynthesis process by interfering with the translocation step in protein synthesis, thus potentially enhancing the activity of eRF1 by increasing the demand for its role in recognizing stop codons during the termination phase of protein synthesis. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin mimics the 3'-end of an aminoacyl-tRNA, and in doing so, it prematurely terminates protein synthesis, thereby potentially increasing the functional activity of eRF1 as it is called upon to release nascent polypeptide chains from the ribosome. | ||||||
Geneticin (G418) Sulfate | 108321-42-2 | sc-29065 sc-29065A sc-29065C sc-29065D sc-29065B | 1 g 5 g 100 g 500 g 25 g | $108.00 $399.00 $1530.00 $6248.00 $469.00 | 193 | |
G418 is an aminoglycoside antibiotic which causes premature chain termination during translation. By doing this, it could indirectly enhance the functional activity of eRF1 by increasing the number of occurrences where termination and ribosome recycling are necessary. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that interferes with the peptidyl transferase activity of the ribosomal 60S subunit. This could indirectly lead to an increased requirement for eRF1 activity to resolve arrested ribosomal complexes during termination. | ||||||
Emetine | 483-18-1 | sc-470668 sc-470668A sc-470668B sc-470668C | 1 mg 10 mg 50 mg 100 mg | $440.00 $900.00 $1400.00 $2502.00 | ||
Emetine inhibits protein elongation by interfering with translocation of the ribosome. This could indirectly necessitate greater activity of eRF1 as it may be required more frequently for the termination of protein synthesis when elongation is compromised. | ||||||
Harringtonin | 26833-85-2 | sc-204771 sc-204771A sc-204771B sc-204771C sc-204771D | 5 mg 10 mg 25 mg 50 mg 100 mg | $250.00 $367.00 $548.00 $730.00 $980.00 | 30 | |
Harringtonine inhibits protein synthesis by preventing the initial elongation step of translation. This could result in an indirect enhancement of eRF1 activity by increasing the number of ribosomes that require termination. | ||||||
Fusidic acid | 6990-06-3 | sc-215065 | 1 g | $292.00 | ||
Fusidic acid is known to prevent the turnover of elongation factor G (EF-G) from the ribosome, potentially causing an accumulation of ribosomes that are stalled and awaiting termination, thereby indirectly increasing the functional demand for eRF1. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $90.00 | 10 | |
Chloramphenicol inhibits bacterial protein synthesis by blocking the peptidyl transferase step on the ribosome. Although its primary activity is on bacterial ribosomes, if it affects eukaryotic ribosomes, it could increase the demand for eRF1 activity in the termination phase. | ||||||
Homoharringtonine | 26833-87-4 | sc-202652 sc-202652A sc-202652B | 1 mg 5 mg 10 mg | $52.00 $125.00 $182.00 | 11 | |
Homoharringtonine is a cephalotaxine ester that inhibits the initiation step and causes the premature termination of protein synthesis. This may indirectly result in an increased functional activity of eRF1 by requiring its action more frequently during the termination process where incomplete proteins are synthesized. | ||||||